• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia

byDavid XiangandHarsh Shah
April 22, 2022
in Chronic Disease, Hematology, Rheumatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Rilzabrutinib was active and 400mg twice daily was identified as the dose for further testing with low-level toxic effects.

2. Rilzabrutinib showed a rapid and durable clinical activity for the management of immune thrombocytopenia.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Immune thrombocytopenia is an acquired autoimmune disorder characterized by immune-mediated platelet destruction and impairment of platelet production. The disease can increase a patient risk of bleeding, hospitalization, death, fatigue, and impaired quality of life. Rilzabrutinib, a BTK inhibitor, has been proposed to potentially increase platelet counts in patients with immune thrombocytopenia through decreased macrophage-mediated platelet destruction and reduced production of pathogenic autoantibodies. However, there is a gap in knowledge as to understanding Rilzabrutinib’s safe and effective dose in patients with immune thrombocytopenia to be further tested in phase 3 clinical trials. This study found that oral Rilzabrutinib led to rapid and durable clinical activity in 40% of patients with immune thrombocytopenia and that a 400mg twice-daily dose was identified to be safe and effective. This study was limited by no standard treatment recommendations that currently exist for patients with immune thrombocytopenia and by a range of time points and platelet-response endpoints. Nevertheless, these study’s findings are significant, as they identify a safe and effective dose for Rilzabrutinib to be used in an ongoing double-blind phase 3 trial comparing Rilzabrutinib with placebo in adults and adolescents with persistent or chronic immune thrombocytopenia, and demonstrate that oral Rilzabrutinib has a rapid and durable clinical activity.

Click to read the study in NEJM

Relevant Reading: Immune Thrombocytopenia Treatment

In-Depth [open label dose-finding clinical trial]: This international, adaptive, open-label, dose-finding, phase 1-2 clinical trial was conducted to evaluate Rilzabrutinib therapy in previously treated patients with immune thrombocytopenia, with 60 patients enrolled. Patients with immune thrombocytopenia who were aged 18 to 80 years, had a platelet count of less than 30×10^2 per cubic millimeter on two occasions and had a response to at least one previous therapy for immune thrombocytopenia were eligible for the study. Patients who were outside of the age range or did not have a response to previous therapies for immune thrombocytopenia, including splenectomy, were excluded from the study. The primary outcome measured was safety and platelet response, defined as at least two consecutive platelet counts of at least 50×10^3 per cubic millimeter and an increase from baseline of at least 20×10^3 per cubic millimeter. Outcomes in the primary analysis were analyzed via the Clopper-Pearson method and Kaplan-Meier analysis for time-to-event estimates. Based on the analysis, at the median of 167.5 days of treatment, 40% of the patients (24 patients) overall met the primary endpoint of platelet response. The median time to first platelet count of at least 50×10^3 per cubic millimeter was 11.5 days among all patients and 12.5 days among the patients who started Rilzabrutinib treatment at the highest dose of 400 mg twice daily. Among the group of patients with a primary platelet response, the mean percentage of weeks with a platelet count of at least 50×10^3 per cubic millimeter was 65%. Overall, this study demonstrated that a dose of 400mg twice-daily of Rilzabrutinib was shown to be safe and effective and that Rilzabrutinib provided a rapid and durable clinical activity in patients with immune thrombocytopenia, supporting the ongoing phase 3 trial that will better elucidate the magnitude and durability of clinical benefit with Rilzabrutinib treatment.

RELATED REPORTS

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

Immune thrombocytopenia and thrombosis mortality predictors following SARS-CoV-2 vaccine

#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Bruton’s tyrosine kinase (BTK) inhibitorBTK inhibitorBTKiimmune thrombocytopeniarilzabrutinib
Previous Post

Endovascular therapy for large ischemic strokes provides better functional outcomes

Next Post

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

RelatedReports

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation
StudyGraphics

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

November 11, 2021
Novel coronavirus identified from patients with pneumonia in Wuhan, China
Cardiology

Immune thrombocytopenia and thrombosis mortality predictors following SARS-CoV-2 vaccine

November 10, 2021
#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia
StudyGraphics

#VisualAbstract Ibrutinib may be beneficial in heavily pretreated patients with classic and variant hairy cell leukemia

July 8, 2021
#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy
StudyGraphics

#VisualAbstract Phase 2 trial shows umbralisib is safe and effective in patients with chronic lymphocytic leukemia who are intolerant to BTK or PI3Kδ inhibitor therapy

June 4, 2021
Next Post
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Widespread population immunity of Covid-19 observed in South Africa before Omicron wave

#VisualAbstract: Odronextamab shows promising clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

#VisualAbstract: Odronextamab shows promising clinical activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
  • Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia
  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options